Therefore, if future studies validate the association between rs2228528 in ERCC6 and response to FOLFIRINOX, using blood samples, a single blood draw could provide an easy and fast way to determine whether to use FOLFIRINOX treatment or gemcitabine-based chemotherapy first in pancreatic cancer patients. This evidence concerns the gene ERCC6 and pancreatic neoplasm.